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Drs J. P. Morgan and J.-Y. Minc
doi:10.1016/j.jtcvs.2005.12.022bjective: The present study was designed to test whether intravenously infused
mbryonic stem cell-derived cells could translocate to injured myocardium after
yocardial infarction and improve cardiac function.
ethods: Cultured embryonic stem cell-derived cells were transfected with
reen fluorescent protein. Embryonic stem cell-derived cells were administered
hrough the tail vein (approximately 107 cells in 1 mL of medium for each rat)
very other day for 6 days in 45 rats after myocardial infarction. Six weeks after
yocardial infarction and cell infusion, cardiac function, blood flow, and the
umeric density of arterioles were measured to test the benefits of cell therapy.
n in vitro Transwell assay was performed to evaluate the embryonic stem cell
igration.
esults: Ventricular function, regional blood flow, and arteriole density were
ignificantly increased in rats receiving intravenously infused embryonic stem
ell-derived cells compared with control rats after myocardial infarction. Histologic
nalysis demonstrated that infused embryonic stem cell-derived cells formed green
uorescent protein-positive grafts in infarcted myocardium. Additionally, positive
mmunostaining for cardiac troponin I was found in hearts after myocardial infarc-
ion receiving embryonic stem cell-derived cell infusion that corresponded to the
reen fluorescent protein-positive staining. The Transwell migration assay indicated
hat cultured neonatal rat cardiomyocytes with overexpression of tumor necrosis
actor  induced greater migration of embryonic stem cells compared with cardio-
yocytes without tumor necrosis factor  expression.
onclusions: Our data demonstrate that intravenously infused embryonic stem
ell-derived cells homed to the infarcted heart, improved cardiac function, and
nhanced regional blood flow at 6 weeks after myocardial infarction. The in
itro migration assay suggested that such a homing mechanism could be asso-
iated with locally released cytokines, such as tumor necrosis factor , that are
pregulated in the setting of acute myocardial infarction and heart failure.
n recent years, cell transplantation has emerged as a potential therapy for
heart failure caused by myocardial infarction (MI).1-6 Initial efforts a
cellular cardiomyoplasty have transplanted satellite cells,1 skeletal myo-
lasts,2 bone marrow-derived cells,5 and fetal cardiomyocytes.6 Embryonic stem
ells (ESCs), which have better plasticity and cardiomyogenic capacity than the
ell types listed above, have also been successfully transplanted into infarcted
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 4 889
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TXodent hearts3,4 and the left ventricular (LV) wall 
ystrophic mice.7 Most of the previous studies deliver
onor cells through intramyocardial injection after car-
iac surgery. The advantage of this approach is that it
raps implanted cells in selected injured areas of the
eart. However, the procedure of intramyocardial injec-
ion is invasive and might not be suitable for patients
ith acute MI or severe congestive heart failure. Re-
ently, Chiu and colleagues8,9 demonstrated the feasibil-
ty of delivering bone marrow stromal cells with coronary
nfusion and indicated that marrow stromal cells could
raffic through the coronary system into injured myocar-
ium and form cardiomyocytes. Mobilized bone marrow
ells, stimulated by stem cell factor or granulocyte col-
ny-stimulating factor, have been shown to repair the
nfarcted mouse heart and improve ventricular function10
t appears that somatic stem cells can migrate to heart
issue and further differentiate into cardiomyocytes.11
MI is associated with inflammatory responses that
nclude upregulation of mast cells, macrophages, and
ssociated inflammatory cytokines. Experimental MI is
lso associated with activation of a series of cytokin12
Figure 1. Confluent culture of EDCs under phase-con
Abbreviations and Acronyms
cTnI  cardiac troponin I
DAPI  4=-6-diamidino-2-phenylindole
dP/dtmax maximum rate of LV systolic
pressure increase
dP/dtmax maximum rate of LV systolic
pressure decrease
EDC  embryonic stem cell-derived cell
ESC  embryonic stem cell
GFP  green fluorescent protein
LV  left ventricular
LVSP  left ventricular systolic pressure
MI myocardial infarction
TNF  tumor necrosis factororiginal magnification 40; C, original magnification 400
90 The Journal of Thoracic and Cardiovascular Surgery ● Apriast cell-derived tumor necrosis factor  (TNF-) re-
eased after myocardial ischemia represents an “up-
tream” cytokine responsible for initiating the inflamma-
ory cascade.12 Released cytokines from injure
yocardium might act as chemoattractants for circulating
onor cell migration. Our previous study indicated that
ouse ESC-derived cells (EDCs) infused intravenously
ere able to migrate into injured myocardium caused by
ncephalomyocarditis virus13 and increased the surviva
ate of recipient mice.
The present study was designed to investigate whether
ntravenously infused EDCs could translocate to injured
yocardium in response to locally released cytokines
fter MI and improve cardiac function. An in vitro cul-
ure system was used for testing whether TNF-, an
nflammatory cytokine that is upregulated in the setting
f acute MI and heart failure, could facilitate EDC mi-
ration responding to cytokine stimulation.
aterials and Methods
DC Preparation and Transplantation
he mouse ESC line ES-D3 was purchased from the American
ype Culture Collection (Manassas, Va) and cultured with the
anding drops method, as previously described.3,4 Before trans-
lantation, cells dissected from beating clusters were trans-
ected with green fluorescent protein (GFP), a marker for iden-
ification of infused cells from host myocardium. Plasmids with
n hCMV IE promoter/enhancer-driving GFP gene (5.7 kb) and
ene PORTER transfection reagent were obtained from Gene
herapy Systems Inc (San Diego, Calif). GFP-labeled EDCs
ould be detected under fluorescent microscopy at the second
ay of transfection, and the transfection efficiency was greater
han 90% (Figure 1). Our previous study demonstrated tha
ction potentials recorded from spontaneously beating EDCs
re very similar to those recorded in neonatal mouse cardiomy-
cytes.3 Two days after GFP transfection, cultured EDCs w
rypsinized and resuspended in Joklik modified medium
Sigma, St Louis, Mo), with a density of approximately 107
ells/mL for cell infusion.
(A, original magnification 40) and fluorescent (B,trast
) microscopy at 3 days after GFP transfection.
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TXExperiments were performed in 45 Wistar male rats (Charles
iver Laboratories, Wilmington, Mass) aged 3 months. The
nvestigation conformed to the “Guide for the care and use of
aboratory animals” published by the US National Institutes of
ealth (publication no. 85-23, revised 1996), and the protocol
as approved by our Institutional Animal Care Committee. MI
as created by means of ligation of the left coronary artery
uring anesthesia with pentobarbital (60 mg/kg administered
ntraperitoneally), as previously described.3,4 Approximately 20
inutes after ligation of the coronary artery, EDCs were ad-
inistered through the tail vein (approximately 107 cells in 1
L of medium for each rat) every other day for 6 days in
xperimental rats after MI. Control rats after MI received the
ame operation but were only infused with the equivalent vol-
me of the cell-free medium. The sham group underwent an
dentical operation with neither ligation of the coronary artery
or cell transplantation.
easurements of Cardiac Function and Infarct Size
emodynamic measurements (8 per group) in vivo were per-
ormed with a modified method, as described previously,3,4 at 6
eeks after MI and cell infusion. The Millar catheter was
arefully advanced into the left ventricle through the carotid
rtery. The LV systolic pressure (LVSP), the LV end-diastolic
ressure, the maximum rate of LV systolic pressure increase
dP/dtmax), and the maximum rate of LV systolic pressure
ecrease (dP/dtmax) were recorded on a computer and ana-
yzed by using a PowerLab data-acquisition system (model
L820; ADInstruments, Colorado Springs, Colo). The rat heart
as harvested after hemodynamic measurement, weighed, and
ormalized by body weight. Subsequently, the hearts were
ransversely sectioned into 4 pieces from the apex to the base
nd prepared for infarct size measurement and histologic
tudy.3,4
easurements of Regional Blood Flow and Numeric
ensity of Arterioles
n another set of animals (7 per group), stable isotope-labeled
icrospheres (15 m; BioPAL Inc, Worcester, Mass) were
sed to determine the regional blood flow in anesthetized rats.
he method was modified from a previous publication.14 In
rief, a set of microspheres (1.25  106 in 0.5 mL) was diluted
n 0.5 mL of sanSaline saline (BioPAL Inc) and injected into
he left atrium over 10 seconds. Reference blood samples were
ithdrawn by using a standard syringe pump (model PHD
000; Harvard-Apparatus, Holliston, Mass) at a constant rate of
-minute intervals through the femoral artery, resulting in a
-mL sample used to calculate absolute myocardial blood flow.
he rat heart was then harvested after achievement of anesthe-
ia. The left ventricle was surgically isolated and cut into
ransmural slices, which were further subdivided into transmu-
al segments. Each segment contained approximately equal
oncentrations of the endocardium and epicardium. The average
yocardial sample weighed approximately 0.15 g. Finally, the
issues and blood samples were shipped to BioPAL Inc for
easurement of isotope microspheres and determination of
yocardial blood flow. In addition, the numeric density ofrterioles larger than 20 m in diameter was counted in each G
The Journal of Thoracicrea observed (5 rats for each group and 5 random high-power
elds in each rat) on hematoxylin and eosin-stained slides under
ight microscopy at 400 magnification. The number of arte-
ioles in each section was averaged and expressed as the num-
er of arterioles per square millimeter.
istologic Study to Identify Donor Cells
he survival of engrafted EDCs was identified by using GFP-
ositive tissues in paraffin-embedded sections made from rat
earts after MI and cell infusion. Transverse sections were also
ade across the major axis of the liver, lung, kidney, thymus,
nd spleen in each rat. The hearts were sectioned at 5-m
hickness and stained with hematoxylin and eosin. Survived
nfused cells were confirmed by means of identification of GFP
xpression under fluorescent microscopy and immunostaining
or GFP antibody (Abcam, Cambridge, Mass). The secondary
ntibody was anti-rabbit IgG horseradish peroxidase, and the
olor was produced with diaminobenzidine (DAKO, Carpinte-
ia, Calif). Endogenous peroxides were blocked with DAKO
eroxide-blocking reagent (DAKO). Rabbit IgG was used as an
sotype control. New differentiated cardiac tissues from infused
DCs were verified by means of positive immunostaining of
oat anti-cardiac troponin I (cTnI) polyclonal antibodies (Santa
ruz Biotechnology Inc, Santa Cruz, Calif). Positive stains
ere recognized by adding secondary antibodies of chicken
nti-goat IgG 594 (Molecular Probes, Eugene, Ore). Nuclei
ere identified by means of 4=-6-diamidino-2-phenylindole
DAPI) staining. Nonspecific binding was blocked through in-
ubation with protein-blocking solution (DAKO). We then es-
imated the area of GFP-positive spots in each sample of
yocardial sections (5 rat hearts received EDC infusion) and
ounted the GFP-positive spots in eight 200 fields that cov-
red the whole heart section. The percentage of surviving cells
as calculated by dividing the estimated total area of the left
entricle by the area of GFP-positive spots by using a National
nstitutes of Health imaging system. The resulting percentage
as assumed to be the percentage of surviving cells in the heart
hat derived from donor stem cells previously infused.
SC Migration Assay In Vitro
igration of ESCs was assessed in Transwell plates of 6.5-mm
iameter with 5- m pore filters (Figure 2, A ). Mouse embryoni
broblast feeder cells (STO, American Type Culture Collec-
ion) were plated at 3  104 cells/well on fibronectin-coated
lters. The adherent cells were cultured for 2 days to obtain
onfluent STO monolayers. Each lower compartment at the
ottom was plated with neonatal rat myocytes. Myocytes in the
reated group were transfected with TNF- cDNA. Cultured
eonatal rat myocytes (80% confluence) plated in TI-75 flasks
ere transfected with TNF- cDNA (5 L, 9.9  1011 parti-
les/mL). The content of TNF- released by cardiomyocytes
nto the culture medium was measured with a commercial
nzyme-linked immunosorbent assay kit specifically designed
or detection of mouse TNF- (R&D Systems, Inc, Minneapo-
is, Minn; n  7). Before adding ESCs to the upper compart-
ents, STO monolayers were treated with mitomycin-C (10
/mL) for 90 minutes and washed 3 times with culture medium.
FP-tagged ESCs (6  104 cells) were added to each upper
and Cardiovascular Surgery ● Volume 131, Number 4 891
co
5
D
A
d
s
a
u
t
b
p
R
I
P
S
o
c
c
t
s
v  Ad-
T
a
B
H
H
H
I
V
w
m
M
M
c
w
Cardiothoracic Transplantation Min et al
8
TXompartment. Twenty-four hours after incubation, the number
f migrated GFP-positive cells in the lower compartments (n 
runs) was counted during fluorescent microscopy.
ata Analysis
ll values are presented as means  standard deviation. Data
erived from 3 groups in the animal study with repeated mea-
urements were evaluated by means of 1-way analysis of vari-
nce (ANOVA). If ANOVA showed a significant difference, an
npaired Student t test with the Bonferroni correction was used
o compare 2 individual groups. The results of migration assay
etween 2 individual groups were compared by using the un-
aired Student t test.
esults
mprovement of Cardiac Function and Blood
erfusion After Intravenous Infusion of EDCs
ix weeks after intravenous infusion of EDCs, the ratio
f heart weight to body weight was significantly in-
reased in the MI control and MI-EDC infusion groups
Figure 2. Diagram of embryonic stem cell (ESC) migratio
of Transwell plates contained one 3-mm glass cover slip
(GFP)-tagged ESCs were added to the upper compartmen
24 hours. Migrated GFP-positive cells on each cover slip
tumor necrosis factor  (TNF-)–transfected myocytes. E
myocytes from the lower compartments of the Transw
GFP-positive ESCswere detected on the cover slips seede
myocytes, which indicated that greater ESC migration re
cells in the lower compartments that were migrated from
in panel D. TNF-, The group of TNF--transfected neona
without TNF- transfection. **P < .01, Control group verompared with that seen in the sham-operated group. Cell M
92 The Journal of Thoracic and Cardiovascular Surgery ● Apriherapy in rats after MI partially attenuated not only the
everity of cardiac hypertrophy but also the infarcted area
ersus that seen in control rats after MI (Table 1).
say with Transwell plates (A). Each lower compartment
d with neonatal rat myocytes. Green fluorescent protein
the Transwell dishes and cocultured with myocytes for
counted during fluorescent microscopy for control and
nt production of TNF- in control and TNF- transfected
shown in panel B. Panel C demonstrates that more
h TNF--transfected myocytes than on those with control
ded to TNF- overexpression. The average GFP-positive
upper compartments at 24 hours after culture are shown
at myocytes; Control, the group of neonatal rat myocytes
NF- group.
ABLE 1. General characteristics of sham-operated rats
nd rats after MI after EDC infusion
Sham MI  control MI  IV EDCs
W (g) 432 12 411  15 421  18
W (g) 1.0 0.1 1.3  0.4 1.2  0.3
W/BW*100 0.23 0.03 0.32  0.04* 0.28  0.03*†
R (beats/min) 390 26 402  27 411  30
nfarct size (%) 41 6 32 4†
alues are presented as means  standard deviation. Measurements
ere conducted at 6 weeks after embryonic stem cell-derived cell or
edium infusion in 8 rats for each group. Sham, Sham-operated rats;
Icontrol, myocardial infarction rats with cell-free medium infusion;
IIV EDCs, myocardial infarction rats with embryonic stem cell-derived
ell infusion; BW, body weight; HW, heart weight; HW/BW, ratio of heart
eight/body weight; HR, heart rate. *P .01 versus sham group; †P .05,n as
plate
ts of
were
fficie
ell is
d wit
spon
the
tal r
sus TI  IV EDC group versus MI  control group.
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TXitionally, the control rats after MI had a lower LVSP,
ower dP/dtmax, lower dP/dtmax, and higher LV
nd-diastolic pressure compared with values in the sham
nd MI cell-treated groups (Figure 3). EDC infusion 
eeks after MI significantly improved cardiac function,
eflected by an increase in LVSP, dP/dtmax, and dP/
tmax (Figure 3). Additionally, the regional blood fl
ssessed by isotope microspheres and the arteriole den-
ity were significantly decreased in the rats after MI
Figure 4). EDC infusion significantly increased the 
yocardial blood perfusion and the numeric density of
rterioles compared with that seen in the MI control
roup.
istologic Study and Identification of Infused EDCs
ematoxylin and eosin staining of heart sections from
ats after MI receiving cell therapy showed less necrosis
Figure 4. Left ventricular blood flow measured with
group). Numeric densities of arterioles are shown i
intravenously infused embryonic stem cell– derive
perfusion and enhanced angiogenesis at 6 weeks af
Sham-operated rats; MIControl, rats after MI with c
EDC infusion. **P < .01 versus sham group; #P < .05 ve
The Journal of Thoracicn infarcted and surrounding areas at 6 weeks after cell
nfusion (Figure 5). Significant fibrosis was found
ostinfarcted myocardium in the control hearts after MI
ithout cell infusion. Paraffin-embedded sections from
at hearts after MI at 6 weeks after cell treatment showed
FP-positive spots under fluorescent microscopy that
ere further stained positively with GFP antibody (F
re 6). In contrast, sections from sham-operated he
nd control hearts after MI had no such GFP-positive
issue stained with GFP antibody. Positive immunostain-
ng for cTnI was found in EDC-infused hearts after MI
hat corresponded to GFP-positive spots (Figure 
hese data suggest that infused EDCs not only survived
n injured myocardium but also differentiated into car-
iac tissue. In addition, GFP-positive cells were not
dentified outside the infarcted hearts, except in the
Figure 3. Cardiac function assessed with a
Millar catheter in experimental rats at 6
weeks after myocardial infarction (MI) and
embryonic stem cell-derived cell (EDC) in-
fusion through tail vein injection. A, Left
ventricular systolic pressure (LVSP); B, left
ventricular end-diastolic pressure (LVEDP);
C, maximum rate of peak left ventricular
systolic pressure increase (dP/dtmax); D,
maximum rate of peak left ventricular sys-
tolic pressure decrease (dP/dtmax).
Sham, Sham-operated rats; MIControl,
rats after with cell-free medium infusion;
MIIV EDCs, rats after MI with EDC infu-
sion (n  8 in each group). *P < .05 and **P
< .01 versus sham group; #P < .05 versus
MIControl group.
ope microspheres is shown in panel A (7 for each
nel B (8 for each group). The results indicated that
lls (EDCs) significantly improved regional blood
yocardial infarction (MI) and EDC treatment. Sham,
ree medium infusion; MIIV EDCs, rats after MI withisot
n pa
d ce
ter m
ell-frsus MIControl group.
and Cardiovascular Surgery ● Volume 131, Number 4 893
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TXpleen, which contained some GFP-positive areas but
tained negative to troponin I (data not shown). The
urviving cells examined in a cross-section of the heart
ere identified as expressing GFP in the group of rats
fter MI receiving cell infusion. The average percentage
f GFP-positive cells was 5.3% of the total left ventricle.
n Vitro Assay of TNF--Induced ESC Migration
he lower compartments of the Transwell plates were
ultured with neonatal rat cardiomyocytes with or with-
ut transfection of TNF- cDNA. The amount of TNF-
roduction was significantly increased in myocytes trans-
ected with TNF- compared with that from the control
yocytes in culture medium of the lower compartments
Figure 2, B ; n  7 runs for each). Figure 2, C and D (n
5 runs for each), demonstrate significantly greater ESC
igration in response to TNF- incubated for 24 hours
fter adding GFP-tagged ESCs to the upper compart-
ents. These data suggest that cultured neonatal rat car-
iomyocytes with overexpression of TNF- attract more
SCs migrating from the upper compartment to the lower
ompartment.
iscussion
ell transplantation has emerged as a potential therapy to
Figure 5. Representative rat myocardium stained with hema-
toxylin and eosin were from a rat at 6 weeks after myocardial
infarction (MI) with cell-free medium infusion (A and B) and a
rat at 6 weeks after MI and embryonic stem cell-derived cell
(EDC) tail vein infusion (C and D). Cell grafts were clearly
found within the infarcted zone in infracted myocardium after
EDC infusion. In contrast, the tissue in the infarcted regions of
the control myocardium appeared fibrotic and relatively
acellular.reat cardiac dysfunction resulting from MI. Various cell
94 The Journal of Thoracic and Cardiovascular Surgery ● Apriypes appear to be promising candidates because of their
bility to integrate into the host heart tissue1-6,15,16 and
mprove cardiac function.1-6,17 Differentiation efficiency
f bone marrow-derived stem cells into adult cardiomy-
cytes appears limited.18 ESCs, on the other hand, a
luripotent cells derived from the early embryo and retain
he ability to differentiate into all cell types, including
ardiomyocytes.19,20 The availability of human ESCs a
he technique of development for enrichment of cardio-
yocytes derived from human ESCs has paved a possible
ay to use ESCs for a therapeutic approach for animal
tudy and clinical application. Our previous studie3,4
emonstrated that ESCs could be implanted into rat myo-
ardium with intramyocardial injection after MI. The
iability and regeneration capacity of engrafted ESCs
ere demonstrated by their positive immunostaining for
-myosin heavy chain and cTnI. Studies have also shown
he feasibility of transcoronary infusion of donor cells
nto the intact rat heart,21 doxorubicin-induced failing ra
eart,22 and infarcted rat heart.9 However, the clinica
ituation during the early stage of MI might be suitable
either for invasive cardiothoracic surgery with in-
ramyocardial injection of cells nor for relatively less
nvasive interventional catheterization. Such surgical or
nvasive procedures might be associated with high mor-
ality in critically ill patients. Moreover, intracoronary
Figure 6. Infused embryonic stem cell-derived cells (EDCs) in
postinfarcted rat myocardium were identified at 6 weeks after
myocardial infarction (MI) and tail vein injection. Infused cells
were clearly seen in the infarcted area with green fluorescent
protein (GFP) fluorescence (A) and further verified positive to
GFP antibodies (D), which demonstrated that circulating in-
fused EDCs could home to injured myocardium. Panel B shows
the nuclear staining with DAPI, and panel C shows the merge
o
lf GFP and DAPI staining. (Original magnification 200.)
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TXell transplantation has an apparent disadvantage because
f the risk of coronary embolism.21
Recent studies demonstrated that intravenously in-
used donor cells can migrate to an injury site23,24 and
nduce angiogenesis24 in a rat model of stroke. It has 
hown that an animal model of MI25 is associated with
nflammatory infiltration, which is abundant on days 2 to
but gradually decreases and disappears on day 7 after
I. Our present study indicates that intravenously ad-
inistrated EDCs can traffic through the circulation to
ostinfarcted myocardium and differentiate into cardiac
issue. The mechanism might be associated with the
nflammatory response after MI, and locally released
ytokines might facilitate infused EDC migration toward
njured myocardium.
Orlic and associates10 reported that subcutaneous in-
ection of stem cell factor or granulocyte colony-stimu-
ating factor facilitated translocation of native bone mar-
ow cells into infarcted myocardium, resulting in a
ignificant degree of tissue differentiation 27 days later.
owever, recruitment of endogenous adult stem cells
fter ischemic injury might not be enough to achieve
unctional improvement. Our data demonstrated that in-
ravenously infused EDCs can translocate to injured
yocardium through the circulation. No significant num-
ers of GFP-positive donor cells were found in nonin-
ured organs, including the lung, kidney, and liver, except
or the spleen, in which a few GFP-positive spots were
ound (data not shown). Trapped EDCs might infiltrate
hrough vessels into injured myocardium. Within a suit-
ble surrounding niche, infused EDCs differentiated into
ew cardiac-like tissue to replace dead or damaged myo-
ardium, which was supported by positive staining to
TnI in the grafts. Moreover, cardiac protective factors
eg, vascular growth factor) might be released from in-
used EDCs, which not only rescue damaged cardiac
issue but also promote angiogenesis, as reflected by the
nhancement of regional blood perfusion and increased
umbers of arterioles observed in the present study.
herefore the beneficial effects on improvement of car-
iac function and the reduction of infarct size after EDC
nfusion might result from the synergistic effects of myo-
enesis and angiogenesis. Other factors, such as the
ntiapoptotic role of engrafted stem cells, might also
artially contribute to the functional benefits. More ex-
erimental studies are needed to address the mechanisms
f cell transplantation therapy.
The homing response of intravenously infused EDCs
ight be associated with the response to cytokines that
re released locally in injured myocardium. TNF-, a
ember of the proinflammatory cytokines, is considered
o participate in the interactive signal-transduction cas-
ade that regulates inflammatory and immunologic re- o
The Journal of Thoracicponses and triggers leukocyte infiltration through its
hemotactic properties.26 After MI, there is an immedi
nd rapid upregulation of TNF- in the myocardium as
art of the immune system response in the rat MI mod-
l.27 Furthermore, detectable expression of TNF- per-
isted to day 35 after MI. Levels of TNF- protein in the
nfarct and peri-infarct zones increased early to 8- to
0-fold above normal levels and increased to 4- to 5-fold
n the contralateral zone.27 Thus it is reasonable to u
NF- as a representative factor in the cytokine family to
est whether cytokines released from local injured myo-
ardium after MI facilitate migration of infused EDCs.
uring fluorescent microscopy, we detected more GFP-
ositive cells on the cover slips seeded with TNF--
ransfected cardiomyocytes than on cover slips plated
ith control cardiomyocytes. Cardiomyocytes with over-
xpression of TNF- attracted more ESCs, which mi-
rated from one compartment to another in response to
NF- stimulation. This finding suggests that cytokines
roduced by injured myocardium after acute MI perform
major role as chemoattractants for intravenously in-
used EDCs and result in infused cells migrating into
ites of injury. Using a Dunn chamber (a direct viewing
hemotaxis chamber with concentric wells), we recently
howed that ESCs are highly motile and respond to
ifferent concentrations of TNF- in a dose-related man-
er.28 In addition, our previous study29 indicated that th
olecular pathway of stem cell migration stimulated by
xcessive TNF- is through the type II TNF- receptor.
ctivation of p38 and JNK is required for TNF--en-
anced stem cell migration.
There are several limitations to the present study.
nterpreting the functional benefits of EDC infusion in
ats after MI should be done cautiously because cardiac
unction was measured in unloaded experimental condi-
ion and different loading conditions might affect func-
ional results measured with a Millar catheter. A previous
tudy30 demonstrated that intravenously infused bo
arrow-derived mesenchymal stem cells at 1 week after
nfusion were trapped either in the infarcted or border
one and also lodged in the lung, liver, spleen, and bone
arrow. However, the present study indicated that in-
used donor cells were identified only in the infarcted
eart and the spleen at 6 weeks after MI and cell infusion.
hese differential results might be related to the different
ime points chosen to track the fate of infused donor cells
mong various studies.
In conclusion, the present study indicates that intra-
enously infused EDCs can traffic through the circulation
nto injured myocardium. The migration of infused EDCs
ight be associated with local cytokine release after
cute MI. EDCs homing to injured myocardium because
f chemotactic properties of inflammatory cytokines re-
and Cardiovascular Surgery ● Volume 131, Number 4 895
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TXeased locally could differentiate into cardiac tissue and
mprove ventricular function. The functional benefits are
lso related to enhancement of regional blood perfusion
n infarcted myocardium after EDC infusion. The present
trategy simplifies the pathway for cell delivery by using
ntravenous infusion. This approach could potentially be
sed in either severe heart failure or during the acute
hase of MI in a critically ill patient who might not
olerate cell transplantation through surgical operation or
nvasive catheterization.
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